At present, a mere 2% of over 1.47 lakh patients suffering from multi drug resistant tuberculosis (MDR-TB) in India are currently getting Bedaquiline – a newer drug which is safer and more effective. Despite benefits of the drug, its high price remains a significant barrier for the government to make it available to all the patients enrolled with it.
